1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Tengion, Inc.

Tengion, Inc.

TNGNQ
Tengion, Inc.US flagOther OTC
0.00
USD
- -
- -
4,025.00Market Cap
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
2012 Y
2013 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-565.84
-801.63
-629.51
-32.18
-8.82
-7.13
-4.7
-2.98
Free Cash Flow per Basic Share
-514.82
-556.46
-377.22
-21.27
-10.16
-8.22
-4.29
-0.89
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-1,189.64
-2,038.4
-2,603.66
-229.61
-106.49
-104.12
-66.13
-15.56
Tangible Book Value per Share
-1,171.8
-1,999.8
-2,553.25
12.03
2.32
-4.78
-4.19
-3.85
Basic Weighted Avg Shares
- -
- -
- -
1
2
2
4
22
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
4
5
5
5
3
- -
- -
- -
Net Income, GAAP
-31
-42
-30
-26
-19
-17
-19
-64
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
63
41
3
4
7
-5
5
-53
LT Debt
26
21
9
5
3
9
26
33
Total Equity
-82
-135
-178
11
5
-11
-17
-83
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
1.44
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'14
Jun'14
Sep'14
ST Debt
1
1
1
LT Borrowings
29
30
33
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18
22
26
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Mar'14
Jun'14
Sep'14
Total Current Assets
16
11
6
Cash, Cash Equivalents & STI
15
10
6
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
39
50
60
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-81.32%
48.6%
Free Cash Flow
- -
-13.21%
-11.53%
Net Income, GAAP
- -
-13.75%
11.8%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
-2.09
-1.4
-1.87
-1.72
-7.13
2013
-2.11
-3.59
-1.7
- -
-4.7
2014
-1.91
-0.82
-0.73
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2012
- -
- -
- -
- -
- -
2013
- -
- -
- -
- -
- -
2014
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
David I. Scheer
Full Time Employees
25
Sector
Healthcare
Industry
Biotechnology
Address
3929 Westpoint Boulevard Winston-Salem United States of America
IPO Date
Nov 23, 2022
Website
tengion.com
Similar Companies
ISR Immune System Regulation Holding AB (publ) (ISR.ST)
CG Invites Co., Ltd. (083790.KQ)
Kodiak Sciences Inc. (KOD)
Adial Pharmaceuticals, Inc. WT EXP 073123 (ADILW)
Allakos Inc. (ALLK)
Wuhan YZY Biopharma Co Ltd (2496.HK)
Business
Tengion, Inc. was a pioneering entity in the regenerative medicine sector, dedicated to the discovery, development, production, and commercialization of advanced neo-organs and cellular products. The company's innovative approach involved utilizing living cells, sometimes combined with synthetic or natural materials, for implantation or injection into the body. The goal of these therapies was to foster engraftment, regeneration, or replacement of damaged tissues or organs. Among its key initiatives was the Neo-Kidney Augment, an experimental treatment designed to improve renal function in individuals with advanced chronic kidney disease, aiming to defer or eliminate the need for dialysis. Another significant candidate, the Neo-Urinary Conduit, which had reached Phase I clinical trials, sought to offer an alternative to traditional bowel tissue reconstruction for bladder cancer patients requiring a urinary diversion after bladder removal. The company also held a licensing arrangement with Children's Medical Center Corporation (CMCC) for specific patent and intellectual property rights concerning tissue engineering advancements. Established in 2003, Tengion, Inc. was based in Winston-Salem, North Carolina, and ultimately ceased operations, filing for voluntary Chapter 7 liquidation on December 29, 2014, in the U.S. Bankruptcy Court for the District of Delaware.